04.12.24 -- Impacts Of The Inflation Reduction Act (IRA)

During an extraordinary discussion with a historic biotech entrepreneur, he matter-of-factly interjects, “We’re leaving mRNA vaccines in the dust and moving onto a different approach to vaccines.” That ‘dust-generating’ approach is a proprietary T cell-based platform. And it has COVID and many other implications.

Learn how outsourcing this key aspect of bringing product to market can benefit your organization and overall supply chain optimization.

As interest in HPAPIs as powerful therapeutic mechanisms continues to grow, drug manufacturers must design thoughtful risk-based containment strategies to protect employees and ensure safety.

To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.

Discover how an integrated services offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.

Examine several important factors needed to effectively support oral solid dosage therapeutic manufacturing and overcome the complexities involved.

Our team uses a holistic approach to understand and solve important tableting problems like capping, lamination, picking, and sticking. We integrate scientific information to understand and decode root causes of common tableting issues.

Understand the benefits of partnering with a CRO/CDMO partner that has the drug development and manufacturing capabilities to seamlessly move compounds from one phase to the next.